Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Lacrista Venable

Nurse Practitioner, Family Boerne, TX Nurse Practitioner

NPI 1265991780 CMS profile 10784836

103 Dry Crk, Boerne, TX 78006

Open in the dashboard

General payments

$5,257

224 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lacrista Venable of Boerne, TX is reported in the CMS Open Payments database as having received $5,257 across 224 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $21 1
2023 General $41 2
2022 General $2,849 97
2021 General $2,346 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lacrista Venable
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Lacrista Venable were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Lacrista Venable Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,346 $124 $35–$379 $132
2022 $2,849 $141 $44–$430 $149
2023 $41 $154 $49–$476 $160
2024 $21 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Abbott Laboratories $1,281 7 payments
  2. Teva Pharmaceuticals USA, Inc. $590 37 payments
  3. AbbVie, Inc. $583 28 payments
  4. Kyowa Kirin, Inc. $292 11 payments
  5. ACADIA Pharmaceuticals Inc $287 25 payments
  6. Harmony Biosciences LLC $269 11 payments
  7. Biohaven Pharmaceuticals, Inc. $206 7 payments
  8. Novartis Pharmaceuticals Corporation $194 14 payments
  9. Biogen, Inc. $189 11 payments
  10. Neurocrine Biosciences, Inc. $189 16 payments
  11. Other $1,178 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $4,198 218 payments
  2. Travel and Lodging $1,013 4 payments
  3. Education $46 2 payments
Products named General payments · program years 2021–2024
  1. INFINITY $1,281 7 payments
  2. UBRELVY $538 26 payments
  3. AUSTEDO $490 28 payments
  4. NURTEC ODT $293 12 payments
  5. NOURIANZ $292 11 payments
  6. Wakix $269 11 payments
  7. KESIMPTA $174 13 payments
  8. AIMOVIG $170 9 payments
  9. EMGALITY $164 5 payments
  10. OCREVUS $156 7 payments
  11. Other $1,856 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$225,189

Medicare's payments for the services billed

Medicare patients

47

Average age 72

Services billed

354

22 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 66%
Diabetes 60%
Heart failure 60%
Arthritis 53%
Alzheimer's or dementia 53%
Chronic kidney disease 51%
COPD 49%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record